Hansa Biopharma

R&D

Kidney care raises its ambitions at ASN Kidney Week 2026

Following ASN Kidney Week 2026, pharmaphorum spoke with Hansa Biopharma's Maria Törnsén and Tes Pharma's Andrea Pellacani about the conference.

News

X-ray of kidneys concept, medical imaging

Australia first for Hansa’s Idefirix in commercial kidney tr...

Hansa has announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix.

News

Hansa closes on FDA verdict for transplant drug imlifidase

The FDA has started reviewing Hansa's imlifidase for highly sensitised adults needing a kidney transplant, but not in the requested rapid timeframe.

News

3D Illustration Concept of Human Urinary System Kidneys Anatomy

Hansa gets NICE okay for Idefirix in kidney transplant patie...

Sweden's Hansa Biopharma has claimed a positive opinion from NICE for Idefirix, which becomes the first drug cleared for NHS use in a group of kidney transplant patients for whom finding a

Kidney care raises its ambitions at ASN Kidney Week 2026

Australia first for Hansa’s Idefirix in commercial kidney tr...

Hansa closes on FDA verdict for transplant drug imlifidase

Hansa gets NICE okay for Idefirix in kidney transplant patie...

UK pilots shorter NICE appraisal for new medicines

Discover a new era of healthcare panel engagement: Grounded ...

Hansa Biopharma

Editor's Picks